Twist Bioscience Corporation $TWST Shares Acquired by AlphaQuest LLC

AlphaQuest LLC increased its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 202.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,555 shares of the company’s stock after acquiring an additional 15,101 shares during the period. AlphaQuest LLC’s holdings in Twist Bioscience were worth $635,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock worth $85,000 after buying an additional 302 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Twist Bioscience in the 2nd quarter valued at about $97,000. CWM LLC lifted its position in shares of Twist Bioscience by 61.4% in the third quarter. CWM LLC now owns 4,331 shares of the company’s stock worth $122,000 after purchasing an additional 1,648 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Twist Bioscience by 8.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock worth $222,000 after purchasing an additional 469 shares during the period. Finally, AXQ Capital LP acquired a new stake in shares of Twist Bioscience during the 2nd quarter valued at about $226,000.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $40.00, for a total transaction of $120,000.00. Following the sale, the chief financial officer owned 137,031 shares in the company, valued at $5,481,240. This represents a 2.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 1,605 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $34.56, for a total transaction of $55,468.80. Following the transaction, the chief executive officer owned 874,313 shares in the company, valued at approximately $30,216,257.28. The trade was a 0.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 7,940 shares of company stock valued at $292,643. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Trading Up 3.9%

TWST stock opened at $48.12 on Thursday. The company has a quick ratio of 3.33, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $54.74. The company has a market cap of $2.95 billion, a P/E ratio of -37.59 and a beta of 2.24. The business has a fifty day moving average of $36.23 and a 200-day moving average of $31.84.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company had revenue of $103.70 million during the quarter, compared to the consensus estimate of $100.32 million. The business’s quarterly revenue was up 16.9% on a year-over-year basis. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

TWST has been the topic of several analyst reports. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Stephens initiated coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They set an “overweight” rating and a $41.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Robert W. Baird set a $50.00 price objective on Twist Bioscience in a research report on Tuesday. Finally, Evercore ISI upped their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Tuesday. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $45.88.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.